Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...

Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the ...

China is pumping money into its biotech industry, helping launch a new wave of labs and incubators in the country. Experts say this could slow down American innovation in the biotech space. China's ...

In 2025, fewer biotech deals are getting done, but the dollars behind them are bigger than ever. Having spent years working with emerging and fast-growth life sciences companies, I’ve seen firsthand ...

Biotechnology is no longer distant science fiction; it’s already a growing force in both national security and local economies. It affects everything from how much you pay at the pharmacy to whether ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

China’s biotech sector is surging. For the first time, it now leads the world in clinical trials and new drug licensing. The U.S., once the undisputed leader in pharmaceutical innovation, risks losing ...

In the fast-paced world of biotechnology, success hinges on more than groundbreaking science—it requires the right connections, strategic partnerships, and access to capital. Biotech Showcase delivers ...

Enhertu is also the same general type of drug that Fields worked on for a decade at Seagen, a Bothell-based biotech that sold to Pfizer in 2023 for $43 billion. Two of the Seagen drugs she worked on, ...

Mr. Dreyer is an American editor and writer who lives in Shanghai. Just outside Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and ...

Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...